Ability to understand and willingness to sign an IRB approved written informed consent document. Systemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg per day (dexamethasone or equivalent) on the day of vaccine administration.
Adequate organ function allowing favorable benefit to risk ratio per the treating physician Patient must have advanced solid tumors that have progressed after treatment with standard FDA approved therapies, or for which no effective standard therapy is available, or the subject has a contraindication to standard therapy. Patients with advanced malignancies and limited treatment options with an estimated 5 year survival of less than 50%.